[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2869904B1 - Modulateurs des recepteurs lxr - Google Patents

Modulateurs des recepteurs lxr

Info

Publication number
FR2869904B1
FR2869904B1 FR0404958A FR0404958A FR2869904B1 FR 2869904 B1 FR2869904 B1 FR 2869904B1 FR 0404958 A FR0404958 A FR 0404958A FR 0404958 A FR0404958 A FR 0404958A FR 2869904 B1 FR2869904 B1 FR 2869904B1
Authority
FR
France
Prior art keywords
lxr
modulators
receivers
lxr receivers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0404958A
Other languages
English (en)
Other versions
FR2869904A1 (fr
Inventor
Luc Lebreton
Christine Massardier
Christine Dumas
Pierre Dodey
Philippe Masson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Fournier SAS
Original Assignee
Laboratories Fournier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0404958A priority Critical patent/FR2869904B1/fr
Application filed by Laboratories Fournier SAS filed Critical Laboratories Fournier SAS
Priority to JP2007512270A priority patent/JP4892475B2/ja
Priority to CN2011102511968A priority patent/CN102321020A/zh
Priority to EP05769960A priority patent/EP1742918A1/fr
Priority to CA002564642A priority patent/CA2564642A1/fr
Priority to PCT/FR2005/001139 priority patent/WO2005121093A1/fr
Priority to AU2005251979A priority patent/AU2005251979B2/en
Priority to CNA2005800146178A priority patent/CN1950340A/zh
Publication of FR2869904A1 publication Critical patent/FR2869904A1/fr
Application granted granted Critical
Publication of FR2869904B1 publication Critical patent/FR2869904B1/fr
Priority to US11/593,474 priority patent/US7872021B2/en
Priority to NO20065501A priority patent/NO20065501L/no
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR0404958A 2004-05-07 2004-05-07 Modulateurs des recepteurs lxr Expired - Fee Related FR2869904B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR0404958A FR2869904B1 (fr) 2004-05-07 2004-05-07 Modulateurs des recepteurs lxr
CNA2005800146178A CN1950340A (zh) 2004-05-07 2005-05-09 Lxr受体调节剂
EP05769960A EP1742918A1 (fr) 2004-05-07 2005-05-09 Modulateurs des recepteurs lxr
CA002564642A CA2564642A1 (fr) 2004-05-07 2005-05-09 Modulateurs des recepteurs lxr
PCT/FR2005/001139 WO2005121093A1 (fr) 2004-05-07 2005-05-09 Modulateurs des recepteurs lxr
AU2005251979A AU2005251979B2 (en) 2004-05-07 2005-05-09 LXR receptor modulators
JP2007512270A JP4892475B2 (ja) 2004-05-07 2005-05-09 Lxr受容体モジュレーター
CN2011102511968A CN102321020A (zh) 2004-05-07 2005-05-09 Lxr受体调节剂
US11/593,474 US7872021B2 (en) 2004-05-07 2006-11-07 LXR receptor modulators
NO20065501A NO20065501L (no) 2004-05-07 2006-11-29 Lxr reseptor modulstorer.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0404958A FR2869904B1 (fr) 2004-05-07 2004-05-07 Modulateurs des recepteurs lxr

Publications (2)

Publication Number Publication Date
FR2869904A1 FR2869904A1 (fr) 2005-11-11
FR2869904B1 true FR2869904B1 (fr) 2006-07-28

Family

ID=34945760

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0404958A Expired - Fee Related FR2869904B1 (fr) 2004-05-07 2004-05-07 Modulateurs des recepteurs lxr

Country Status (9)

Country Link
US (1) US7872021B2 (fr)
EP (1) EP1742918A1 (fr)
JP (1) JP4892475B2 (fr)
CN (2) CN1950340A (fr)
AU (1) AU2005251979B2 (fr)
CA (1) CA2564642A1 (fr)
FR (1) FR2869904B1 (fr)
NO (1) NO20065501L (fr)
WO (1) WO2005121093A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
GB0526257D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
ES2393822T3 (es) * 2007-08-13 2012-12-28 F. Hoffmann-La Roche Ag Nuevos derivados de piperazina-amida
US8039493B2 (en) * 2007-09-27 2011-10-18 Hoffmann-La Roche Inc. Biaryl sulfonamide derivatives
CN103517908A (zh) 2010-09-07 2014-01-15 Seoul大学校产学协力财团 二倍半萜化合物及其用途
WO2017007755A1 (fr) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
US11746097B2 (en) 2016-06-24 2023-09-05 Saint Louis University LXR inverse agonists for treatment of cancer
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
EA039417B1 (ru) 2017-08-07 2022-01-25 Родин Терапеутикс, Инк. Бициклические ингибиторы гистондеацетилазы

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001517245A (ja) * 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
BR9811569A (pt) * 1997-07-31 2000-09-19 Elan Pharm Inc Compostos que inibem a adesão de leucócito mediada por vla-4
US6559127B1 (en) * 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
AU751950B2 (en) * 1997-11-24 2002-09-05 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
US6251932B1 (en) * 1998-09-25 2001-06-26 Asta Medica Ag Immunophilin ligands
US6300341B1 (en) * 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US6855708B2 (en) * 2001-03-20 2005-02-15 Merck & Co., Inc. N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors
JP2005022976A (ja) * 2001-07-18 2005-01-27 Ajinomoto Co Inc カルボン酸誘導体
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
ATE453389T1 (de) 2002-03-27 2010-01-15 Smithkline Beecham Corp Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
EP1487776A4 (fr) 2002-03-27 2005-05-25 Smithkline Beecham Corp Composes acides et esters et procedes d'utilisation associes
AU2003228614A1 (en) 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Lxr modulators
WO2003090746A1 (fr) 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles utilises en tant que modulateurs du lxr pour le traitement de maladies cardiovasculaires
DE10229777A1 (de) 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
CA2567343A1 (fr) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. Inhibiteurs sulfonamido n-cycliques de gamma-secretase
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline

Also Published As

Publication number Publication date
CN102321020A (zh) 2012-01-18
NO20065501L (no) 2007-01-30
WO2005121093A1 (fr) 2005-12-22
US20070099960A1 (en) 2007-05-03
AU2005251979B2 (en) 2012-04-12
FR2869904A1 (fr) 2005-11-11
US7872021B2 (en) 2011-01-18
EP1742918A1 (fr) 2007-01-17
AU2005251979A1 (en) 2005-12-22
JP4892475B2 (ja) 2012-03-07
CA2564642A1 (fr) 2005-12-22
CN1950340A (zh) 2007-04-18
JP2007536355A (ja) 2007-12-13

Similar Documents

Publication Publication Date Title
DK1720866T3 (da) Fremgangsmåde
DE602007004461D1 (de) Taktsignals
GB2430289A8 (en) Selective execution of deferred instructions
DE602005012636D1 (de) Erung
NO20043305D0 (no) Preparation of lodixanol
NO20055643D0 (no) Preparation of lodixanol
DK2447252T3 (da) Theramuteinmodulatorer
FR2869904B1 (fr) Modulateurs des recepteurs lxr
MA28368A1 (fr) Modulateurs oxydecahydronaphtalene de hm74
DE112007002678A5 (de) Uhrengehäuse
DE502005005664D1 (de) Chronograph
DE602005027311D1 (de) Empfänger
BRPI0511620A (pt) gaseificador aperfeiçoado
FR2867285B1 (fr) Montre
DE602005006734D1 (de) Uhrwerk
FR2877833B1 (fr) Correcteur de lordoses
SE0601411L (sv) Förfarande vid beredning
FI20055133A0 (fi) Iskulaite
FR2865904B1 (fr) Calecon remonte fesses
FR2887144B3 (fr) Audio vibromasseur
ATA13282004A (de) Massagegerät
GB0510501D0 (en) Display of operational instructions
DE112005000656D2 (de) Farbuhr
AT7230U3 (de) Wasserpfeife
UY3556Q (es) Reloj brazalete

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140131